Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Uni-Bio Raises $18.2 Million; Partners with HeungKong Group

publication date: Jul 20, 2017
Uni-Bio Science, a Hong Kong company focused on diabetes, ophthalmology and dermatology products in China, completed an $18.2 million private placement. The company placed the majority of the new shares ($15.4 million) with HeungKong Group of Guangzhou, which will become a Uni-Bio strategic shareholder with a 14.2% stake. Uni-Bio will now have access to HeungKong's distribution network, and the two companies plan to open jointly-owned biopharma incubators and pursue international M&A opportunities. More details....

Stock Symbol: (HKSE: 690)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital